18 August 2023
Direct Healthcare Professional Communications (DHPC) - Valproate (Depakine®, Depakine Chrono®, Valproate Chrono Sanofi®, Valproate Chrono Desitin®, Orfiril® long, Orfiril®, Valproate Sandoz®, Convulex®)
New information on the potential risk for neurodevelopmental disorders in children of fathers treated with valproate compared to children of fathers treated with lamotrigine or levetiracetam.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar